In Vitro Diagnostics Market

In Vitro Diagnostics Market by Product & Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Specimen (Blood, Saliva), Test Type, Application (Oncology, Autoimmune, CVD, Infectious Diseases) & Region - Global Forecast to 2029

Report Code: MD 3609 Mar, 2024, by marketsandmarkets.com

The global in vitro diagnostics market in terms of revenue was estimated to be worth $85.2 billion in 2024 and is poised to reach $119.4 billion by 2029, growing at a CAGR of 6.9% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the in vitro diagnostics (IVD) market is driven by growing prevalence of chronic & infectious diseases, the increasing geriatric population in developed and developing regions, and rising demand for point-of-care testing.

However, an unfavorable reimbursement scenario will restrain the growth of the IVD market to a certain extent during the forecast period.

In Vitro Diagnostics Market Size, Dynamics & Ecosystem

In Vitro Diagnostics Market Size, Dynamics & Ecosystem

To know about the assumptions considered for the study, Request for Free Sample Report

In Vitro Diagnostics Industry Dynamics

DRIVER: Increasing geriatric population and subsequent rise in chronic & infectious diseases

With the rapid growth in the geriatric population globally, the prevalence of age-associated diseases is expected to increase significantly. According to the United Nations Department of Economic and Social Affairs (UN DESA) at the world level in 2022, approximately 10 per cent of people worldwide are aged 65 or over. The proportion of older persons in the world is projected to reach nearly 12 per cent in 2030 and 16 per cent in 2050.

With age, the risk of developing diseases increases proportionately—for instance, nearly 80% of the elderly population in the US suffers from at least one chronic condition (Source: CDC). According to the National Council On Aging (NCOA) research, 94.9% percent of adults aged 60 and older have at least one condition, while 78.7% have two or more.

Having high blood cholesterol raises the risk for heart disease, the leading cause of death, and for stroke, the fifth leading cause of death. Diabetes is another chronic disease that affects the senior population since this population is prone to endocrine disorders due to hormonal fluctuations. Hence, the growth in the geriatric population is expected to increase the prevalence of several chronic conditions worldwide and drive the growth of the IVD market.

RESTRAINT: Unfavourable reimbursement

Medicare does not currently provide genetic testing coverage for individuals without a history of cancer. Similarly, according to MedPAC (Medicare Payment Advisory Commission), medical testing has seen a 40% decline in reimbursement over the last 40 years. This decline and additional budgetary concerns among healthcare systems will be a major obstacle to implementing novel diagnostic techniques in clinical laboratories. Besides, the rules governing reimbursement have been tightened in a number of European nations. The restrictions are severe, particularly for creators of innovative diagnostics whose coverage assessment procedure is opaque and differs throughout insurers. The standards for the caliber of evidence required for reimbursement are unclear to inventors of novel diagnostics. This has led to inefficiencies in the creation of innovative diagnoses and a commensurate rise in needless R&D expenses. These changes in the reimbursement scenario are expected to adversely affect growth of the IVD market.

OPPORTUNITY: Growth opportunities in emerging markets

Major players in the IVD industry should expect growth opportunities from developing economies including India, Brazil, China, South Korea, Turkey, Russia, South Africa, and Mexico. This can be attributed to the high disease prevalence, large patient population, improved healthcare infrastructure, increasing disposable income, and growing medical tourism in these countries.

The incidence of tropical diseases, such as Zika, malaria, and chikungunya, has increased significantly in these countries, with South American nations accounting for the highest number of cases. However, the Asia Pacific has emerged as an adaptive and business-friendly hub due to its relatively less-stringent regulations and data requirements. Currently, China is one of the largest investors in R&D. Moreover, various market players are strategically expanding their product portfolios across emerging countries through product launches & approval, collaborations, and expansion. This will support the installation of diagnostic systems in laboratories and contribute to the adoption of IVD.

CHALLENGE: Operational Barriers

Clinical laboratories across major markets are still evolving; technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as NGS and lab-on-a-chip PCR devices. Laboratory space also needs to be reconfigured to meet the requirements of conducting specific diagnostic tests used for pathogen detection to avoid cross-contamination and ensure efficient time management. This results in considerable cost escalation to maintain and operate advanced molecular diagnostic instruments, particularly those capable of handling a single sample type.

However, the shortage of skilled laboratory technicians to operate advanced diagnostic products has hindered overall adoption of in vitro diagnostics, particularly in emerging markets.

In Vitro Diagnostics Market Segmentation & Geographical Spread

In Vitro Diagnostics Market Segmentation & Geographical Spread

To know about the assumptions considered for the study, download the pdf brochure

Blood, serum, and plasma segment accounted for the largest share of the in vitro diagnostics industry in 2023, by specimen.

Based on specimen, the IVD market is segmented into blood, serum, and plasma, urine, saliva, and other specimens. The blood, serum, and plasma segment accounted for the largest share in the IVD market in 2023. The significant share of the segment can be attributed to the growing number of blood donations. Also, blood is the most widely collected sample for IVD diagnostic procedures, and these are preferred for overall health screening as they provide information on various health conditions, such as genetic disorders, cardiovascular diseases, cancer, and diabetes.

Hospital & clinics segment accounted for the largest share in the in vitro diagnostics industry in 2023, by end user.

Based on end user, the IVD market is segmented into hospital & clinics, clinical laboratories, blood banks, home care settings, pharmaceutical & biotechnology companies, academic institutes, and other end users. In 2023, hospital & clinics accounted for the largest share in the IVD market. Rising number of patient admissions due to infectious diseases have increased the adoption and use of in vitro diagnostic tests across hospital laboratories, thereby driving the market growth.

North America accounted for the largest share of the in vitro diagnostics industry in 2023.

Based on region, the IVD market is segmented into six major regions—North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries. In 2023, North America accounted for the largest share in the IVD market. The large share of this region in the global IVD market is mainly attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments. However, healthcare coverage expansions made by Medicare, Medicaid, and private health insurance companies in the region are also expected to play a significant role in fuelling the growth of the IVD market.

The major players in this market are Roche Diagnostics (Switzerland), Abbott Laboratories (US, Danaher Corporation (US), Siemens Healthineers (Germany), and Thermo Fisher Scientific.These players’ market leadership is due to their comprehensive product portfolios and expansive global footprint. These dominant market players have several advantages, including strong research and development budgets, strong marketing and distribution networks, and well-established brand recognition.

Scope of the In Vitro Diagnostics Industry

Report Metric

Details

Market Revenue in 2024

$85.2 billion

Projected Revenue by 2029

$119.4 billion

Revenue Rate

Poised to Grow at a CAGR of 6.9%

Market Driver

Increasing geriatric population and subsequent rise in chronic & infectious diseases

Market Opportunity

Growth opportunities in emerging markets

This research report categorizes the In Vitro Diagnostics Market to forecast revenue and analyze trends in each of the following submarkets:

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
  • GCC Countries

By Product & Service

  • Reagents & Kits
  • Instruments
  • Data Management Software and Services

By Technology

  • Immunoassays
  • Clinical Chemistry
  • Molecular Diagnostics
  • Hematology
  • Microbiology
  • Coagulation & Hemostasis
  • Urinalysis
  • Chromatography & Mass Spectrometry

By Specimen

  • Blood, Serum, and Plasma
  • Saliva
  • Urine
  • Other Specimens

By Application Split

  • Infectious Diseases
  • Oncology
  • Endocrinology
  • Cardiology
  • Blood Screening
  • Genetic Testing
  • Autoimmune Diseases
  • Allergy Diagnostics
  • Drug Monitoring & Testing
  • Bone & Mineral Disorders
  • Coagulation Testing
  • Blood Group Typing
  • Other Applications

By End User

  • Hospital & Clinics
  • Clinical Laboratories
  • Blood Banks
  • Home Care Settings
  • Pharmaceutical & Biotechnology Companies
  • Academic Institutes
  • Other End Users

Recent Developments of In Vitro Diagnostics Industry:

  • In December 2023, Thermo Fisher launched the applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit and the Thermo Scientific KingFisher Apex Dx, an automated nucleic acid purification device, for the separation and purification of bacterial and viral pathogens from respiratory biological specimens.
  • In November 2023, Roche launched a Elecsys Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays for the detection of hepatitis E virus (HEV) infections in countries accepting the CE mark .
  • In July 2023, Siemens received FDA clearance and launched its Atellica CI Analyzer for immunoassay and clinical chemistry in the world’s major markets.
  • In August 2022, Roche launched a Digital LightCycler System, a digital polymerase chain reaction (PCR) system. This system is a powerful new diagnostics platform combatting cancer and other diseases.
  • In November 2022, Danaher Corporation launched the Xpert Xpress MVP, a multiplexed PCR test.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 82)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
    1.3 INCLUSIONS & EXCLUSIONS 
    1.4 MARKET SCOPE 
           1.4.1 MARKETS COVERED
                    FIGURE 1 MARKET SEGMENTATION
           1.4.2 REGIONS COVERED
           1.4.3 YEARS CONSIDERED
           1.4.4 CURRENCY CONSIDERED
    1.5 MARKET STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
           1.6.1 MARKET RECONCILIATION:
    1.7 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 88)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    2.2.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 5 REVENUE SHARE ANALYSIS
                                FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
                                FIGURE 7 IN VITRO DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS 
    2.5 STUDY ASSUMPTIONS 
    2.6 GROWTH RATE ASSUMPTIONS 
    2.7 RESEARCH LIMITATIONS 
           2.7.1 METHODOLOGY-RELATED LIMITATIONS
           2.7.2 SCOPE-RELATED LIMITATIONS
    2.8 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT ANALYSIS
    2.9 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 101)
    FIGURE 9 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
    FIGURE 10 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    FIGURE 11 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
    FIGURE 12 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 13 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
    FIGURE 14 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    FIGURE 15 GEOGRAPHIC SNAPSHOT OF IVD MARKET
 
4 PREMIUM INSIGHTS (Page No. - 107)
    4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW 
          FIGURE 16 GROWING FOCUS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
    4.2 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2023) 
          FIGURE 17 REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
    4.3 IN VITRO DIAGNOSTICS MARKET: REGIONAL MIX 
          FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
    4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
    4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING ECONOMIES VS. DEVELOPED ECONOMIES 
          FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 111)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing geriatric population and subsequent rise in chronic & infectious diseases
                                TABLE 2 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2022−2050)
                    5.2.1.2 Gradual shift from centralized testing to point-of-care testing
                    5.2.1.3 Growing awareness of early disease diagnosis in emerging economies
                    5.2.1.4 Emergence of rapid PoC technologies and rising adoption of automated analyzers
                                TABLE 3 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES (2021−2023)
                    5.2.1.5 Growing preference for personalized medicine
                    5.2.1.6 Increasing funding for R&D activities
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursements
                    5.2.2.2 Stringent regulatory requirements
                                FIGURE 22 IVDR: CRITICAL AREAS OF IMPACT
                    5.2.2.3 High cost of diagnostic equipment
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Introduction of disease-specific biomarkers and tests
                                TABLE 4 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE
                    5.2.3.2 Growing significance of companion diagnostics
                    5.2.3.3 Growth opportunities in emerging markets
                                TABLE 5 RECENT DEVELOPMENTS IN EMERGING MARKETS
                    5.2.3.4 Improvements in immunoassay diagnostic technologies
                    5.2.3.5 Trend of digitalization
           5.2.4 CHALLENGES
                    5.2.4.1 Operational barriers
                                TABLE 6 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.3 PRICING ANALYSIS 
           5.3.1 INDICATIVE AVERAGE SELLING PRICE OF REAGENTS & KITS (USD), BY REGION
           5.3.2 AVERAGE SELLING PRICE OF IMMUNOASSAY ANALYZERS (USD)
           5.3.3 AVERAGE SELLING PRICE OF LATERAL FLOW ANALYZERS (USD)
           5.3.4 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTICS (USD)
           5.3.5 AVERAGE SELLING PRICE OF CLINICAL CHEMISTRY ANALYZERS (USD)
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 23 IN VITRO DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 24 IN VITRO DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
    5.6 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 7 IN VITRO DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.6.1 INTENSITY OF COMPETITIVE RIVALRY
           5.6.2 BARGAINING POWER OF SUPPLIERS
           5.6.3 BARGAINING POWER OF BUYERS
           5.6.4 THREAT OF NEW ENTRANTS
           5.6.5 THREAT OF SUBSTITUTES
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 25 IN VITRO DIAGNOSTICS MARKET: ECOSYSTEM MAP
           5.7.1 IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
    5.8 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 
          TABLE 8 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.9 REGULATORY ANALYSIS 
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                                TABLE 9 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
                                FIGURE 26 US: REGULATORY PROCESS FOR IVD DEVICES
                    5.9.1.2 Canada
                                FIGURE 27 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
           5.9.2 EUROPE
                    TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES
                    FIGURE 28 EUROPE: IVDR TIMELINE
           5.9.3 ASIA PACIFIC
                    5.9.3.1 Japan
                                FIGURE 29 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
                                TABLE 11 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
                                TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.9.3.2 China
                                TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.9.3.3 India
                                FIGURE 30 INDIA: REGULATORY PROCESS FOR IVD DEVICES
                    5.9.3.4 South Korea
                                TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.9.3.5 Indonesia
                                TABLE 15 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
           5.9.4 RUSSIA
                    TABLE 16 RUSSIA: CLASSIFICATION OF IVD DEVICES
           5.9.5 MIDDLE EAST & AFRICA
                    5.9.5.1 Saudi Arabia
                                TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.9.5.2 Africa
           5.9.6 LATIN AMERICA
                    5.9.6.1 Mexico
                                FIGURE 31 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
                                TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.9.6.2 Brazil
    5.10 PATENT ANALYSIS 
    5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           5.11.1 REVENUE SHIFT FOR IN VITRO DIAGNOSTICS MARKET
    5.12 KEY CONFERENCES & EVENTS 
           TABLE 19 IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024)
    5.13 TECHNOLOGY ANALYSIS 
           5.13.1 IN VITRO DIAGNOSTICS MARKET: KEY TECHNOLOGIES
           5.13.2 IN VITRO DIAGNOSTICS MARKET: ADJACENT TECHNOLOGIES
    5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR IVD PRODUCTS
                     TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD PRODUCTS (%)
           5.14.2 BUYING CRITERIA
                     FIGURE 33 KEY BUYING CRITERIA FOR IVD PRODUCTS
                     TABLE 21 KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS
    5.15 TRADE ANALYSIS 
           5.15.1 TRADE ANALYSIS FOR IVD PRODUCTS
                     TABLE 22 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2018–2022 (USD MILLION)
                     TABLE 23 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2018–2022 (USD MILLION)
 
6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 151)
    6.1 INTRODUCTION 
          TABLE 24 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
    6.2 REAGENTS & KITS 
           6.2.1 INCREASING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET
                    TABLE 25 IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 26 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 27 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 28 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 29 LATIN AMERICA: IN VITRO DIAGNOSTICS FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 30 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2021–2029 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 RISING TREND OF AUTOMATION TO DRIVE MARKET
                    TABLE 31 KEY INSTRUMENTS AVAILABLE IN IVD MARKET
                    TABLE 32 IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 33 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 34 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 35 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 36 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 37 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2029 (USD MILLION)
    6.4 DATA MANAGEMENT SOFTWARE AND SERVICES 
           6.4.1 ABILITY TO IMPROVE OPERATIONAL EFFICIENCY TO SUPPORT MARKET GROWTH
                    TABLE 38 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN IVD MARKET
                    TABLE 39 IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 40 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 41 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 42 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 43 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 44 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DATA MANAGEMENT SOFTWARE AND SERVICES, BY COUNTRY, 2021–2029 (USD MILLION)
 
7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 165)
    7.1 INTRODUCTION 
          TABLE 45 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
    7.2 IMMUNOASSAYS 
          TABLE 46 KEY IMMUNOASSAY ANALYZERS AVAILABLE IN IVD MARKET
          TABLE 47 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
          TABLE 48 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2021–2029 (USD MILLION)
          TABLE 49 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 50 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 ((USD MILLION)
          TABLE 51 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 52 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 53 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
                    7.2.1.1 Utilization in viral disease diagnostics and drug discovery to boost demand
                                TABLE 54 KEY ELISA ANALYZERS AVAILABLE IN IVD MARKET
                                TABLE 55 IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 56 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 57 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 58 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 59 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 60 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021–2029 (USD MILLION)
           7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS
                    7.2.2.1 High sensitivity and wide detection range to fuel market
                                TABLE 61 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET
                                TABLE 62 IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 63 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 64 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 65 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 66 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 67 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.2.3 IMMUNOFLUORESCENCE ASSAYS
                    7.2.3.1 HIV antibody diagnosis in medical research to support market growth
                                TABLE 68 IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 69 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 70 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 71 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 72 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 73 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.2.4 RAPID TESTS
                    7.2.4.1 Rising usage in emergency care to drive market
                                TABLE 74 KEY RAPID TESTS AVAILABLE IN IVD MARKET
                                TABLE 75 IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 76 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 77 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 78 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 79 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 80 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RAPID TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)
                    7.2.5.1 Rapid analysis of samples and high functionality to boost demand
                                TABLE 81 IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 82 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 83 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 84 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 85 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 86 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET ELISPOT, BY COUNTRY, 2021–2029 (USD MILLION)
           7.2.6 WESTERN BLOTTING
                    7.2.6.1 Gold standard for result validation to boost demand
                                TABLE 87 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN IVD MARKET
                                TABLE 88 IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 89 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 90 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 91 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 92 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 93 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2029 (USD MILLION)
           7.2.7 OTHER IMMUNOASSAY TECHNOLOGIES
                    TABLE 94 IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 95 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 96 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 97 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 98 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 99 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER IMMUNOASSAY TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
    7.3 CLINICAL CHEMISTRY 
          TABLE 100 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES
          TABLE 101 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES
          TABLE 102 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
          TABLE 103 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2021–2029 (USD MILLION)
          TABLE 104 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 105 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 106 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 107 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 108 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2021–2029 (USD MILLION)
           7.3.1 BASIC METABOLIC PANELS
                    7.3.1.1 Rising prevalence of diabetes to boost demand
                                TABLE 109 IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 110 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 111 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 112 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 113 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 114 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.3.2 LIVER PANELS
                    7.3.2.1 Rising prevalence of cirrhosis and viral hepatitis to fuel market
                                TABLE 115 IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 116 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 117 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 118 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 119 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 120 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIVER PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.3.3 RENAL PROFILES
                    7.3.3.1 Ability to monitor cytokines & chemokines in urine to propel market
                                TABLE 121 IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 122 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 123 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 124 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 125 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 126 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR RENAL PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
           7.3.4 LIPID PROFILES
                    7.3.4.1 Determination of total cholesterol and risk status for CVD to boost demand
                                TABLE 127 IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 128 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 129 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 130 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 131 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 132 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LIPID PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
           7.3.5 THYROID FUNCTION PANELS
                    7.3.5.1 High incidence of thyroid-related disorders to support market growth
                                TABLE 133 IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 134 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 135 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 136 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 137 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 138 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR THYROID FUNCTION PROFILES, BY COUNTRY, 2021–2029 (USD MILLION)
           7.3.6 ELECTROLYTE PANELS
                    7.3.6.1 Ability to diagnose hypertension and heart failure to support uptake
                                TABLE 139 IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 140 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 141 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 142 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 143 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 144 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.3.7 SPECIALTY CHEMICAL TESTS
                    7.3.7.1 Inclusion of immunosuppressant drug monitoring and drugs of abuse to support market growth
                                TABLE 145 IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 146 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 147 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 148 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 149 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 150 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
    7.4 MOLECULAR DIAGNOSTICS 
          TABLE 151 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN IVD MARKET
          TABLE 152 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
          TABLE 153 IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021–2029 (USD MILLION)
          TABLE 154 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 155 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 156 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 157 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 158 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.4.1 POLYMERASE CHAIN REACTION (PCR)
                    7.4.1.1 High specificity of RT-PCR tests to drive market
                                TABLE 159 KEY PCR INSTRUMENTS AVAILABLE IN IVD MARKET
                                TABLE 160 IN VITRO DIAGNOSTICS MARKET FOR PCR, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 161 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 162 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 163 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 164 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 165 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2021–2029 (USD MILLION)
           7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
                    7.4.2.1 Cost benefits to drive market
                                TABLE 166 IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 167 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 168 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 169 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 170 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 171 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2021–2029 (USD MILLION)
           7.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
                    7.4.3.1 Declining costs of NGS-based tests to boost demand
                                TABLE 172 IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 173 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 174 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 175 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 176 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, 2021–2029 (USD MILLION)
                                TABLE 177 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.4.4 IN SITU HYBRIDIZATION (ISH)
                    7.4.4.1 Rising prevalence of cancer and genetic disorders to drive market
                                TABLE 178 IN VITRO DIAGNOSTICS MARKET FOR ISH, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 179 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 180 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 181 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 182 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 183 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2021–2029 (USD MILLION)
           7.4.5 DNA MICROARRAYS
                    7.4.5.1 High resolution and throughput capabilities to support market growth
                                TABLE 184 IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2021–2029 (USD MILLION)
                                TABLE 185 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 186 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 187 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 188 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)
                                TABLE 189 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
           7.4.7 Other molecular diagnostic technologies include electrophoresis and flow cytometry.
                    TABLE 190 IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 191 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 192 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 193 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 194 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 195 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
    7.5 HEMATOLOGY 
           7.5.1 GROWING FOCUS ON STEM CELL RESEARCH TO BOOST DEMAND
                    TABLE 196 IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 197 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 198 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 199 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 200 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 201 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
    7.6 MICROBIOLOGY 
           7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET
                    TABLE 202 IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 203 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 204 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 205 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 206 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 207 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
    7.7 COAGULATION & HEMOSTASIS 
           7.7.1 GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET
                    TABLE 208 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 209 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 210 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 211 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 212 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 213 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2021–2029 (USD MILLION)
    7.8 URINALYSIS 
           7.8.1 RISING INCIDENCE OF UTIS TO SUPPORT MARKET GROWTH
                    TABLE 214 IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 215 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 216 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 217 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 218 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 219 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINALYSIS, BY COUNTRY, 2021–2029 (USD MILLION)
    7.9 CHROMATOGRAPHY & MASS SPECTROMETRY 
           7.9.1 METHODOLOGICAL IMPROVEMENTS AND TECHNOLOGICAL INNOVATIONS TO FUEL MARKET
                    TABLE 220 IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 221 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 222 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 223 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 224 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 225 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2021–2029 (USD MILLION)
 
8 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN (Page No. - 260)
    8.1 INTRODUCTION 
          TABLE 226 IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
    8.2 BLOOD, SERUM, AND PLASMA 
           8.2.1 HIGH RELIABILITY FOR CHRONIC DISEASE DIAGNOSIS TO PROPEL MARKET
                    TABLE 227 IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 228 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 229 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 230 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 231 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 232 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA, BY COUNTRY, 2021–2029 (USD MILLION)
    8.3 SALIVA 
           8.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED TESTS TO SUPPORT MARKET GROWTH
                    TABLE 233 IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 234 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 235 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 236 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 237 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 238 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SALIVA, BY COUNTRY, 2021–2029 (USD MILLION)
    8.4 URINE 
           8.4.1 INCREASING UTILIZATION IN ILLICIT DRUG TESTING TO BOOST DEMAND
                    TABLE 239 IN VITRO DIAGNOSTICS MARKET FOR URINE, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 240 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 241 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 242 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 243 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 244 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR URINE, BY COUNTRY, 2021–2029 (USD MILLION)
    8.5 OTHER SPECIMENS 
          TABLE 245 IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2021–2029 (USD MILLION)
          TABLE 246 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 247 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 248 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 249 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)
          TABLE 250 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2021–2029 (USD MILLION)
 
9 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 274)
    9.1 INTRODUCTION 
          TABLE 251 IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
    9.2 LABORATORY TESTS 
           9.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND GROWING FOCUS ON EARLY DISEASE DETECTION TO PROPEL MARKET
                    TABLE 252 IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 253 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 254 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 255 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 256 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 257 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
    9.3 POINT-OF-CARE TESTS 
           9.3.1 RAPID RESULTS AND HIGH CONVENIENCE TO BOOST DEMAND
                    TABLE 258 IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 259 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 260 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 261 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 262 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 263 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
 
10 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 282)
     10.1 INTRODUCTION 
             TABLE 264 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
     10.2 INFECTIOUS DISEASES 
             10.2.1 INCREASING PREVALENCE OF TB AND TYPHOID TO BOOST DEMAND
                        TABLE 265 IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 266 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 267 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 268 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 269 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 270 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
     10.3 ONCOLOGY 
             10.3.1 HIGH INCIDENCE OF BREAST CANCER TO PROPEL MARKET
                        TABLE 271 INCREASING INCIDENCE OF CANCER, BY REGION, 2022 VS. 2040
                        TABLE 272 IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 273 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 274 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 275 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 276 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 277 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
     10.4 ENDOCRINOLOGY 
             10.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO DRIVE MARKET
                        TABLE 278 IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 279 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 280 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 281 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 282 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 283 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
     10.5 CARDIOLOGY 
             10.5.1 INCREASING USE OF IMMUNOASSAYS IN CVD DETECTION TO FUEL MARKET
                        TABLE 284 IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 285 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 286 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 287 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 288 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 289 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)
     10.6 BLOOD SCREENING 
             10.6.1 RISING INCIDENCE OF HIV AND SYPHILIS TO SUPPORT MARKET GROWTH
                        TABLE 290 IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 291 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 292 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 293 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 294 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 295 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2021–2029 (USD MILLION)
     10.7 GENETIC TESTING 
             10.7.1 DIAGNOSIS OF RARE DISEASES TO SUPPORT MARKET GROWTH
                        TABLE 296 IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 297 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 298 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 299 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 300 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 301 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
     10.8 AUTOIMMUNE DISEASES 
             10.8.1 GROWING DEMAND FOR AUTOIMMUNITY ASSAYS TO DRIVE MARKET
                        TABLE 302 IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 303 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 304 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 305 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 306 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 307 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
     10.9 ALLERGY DIAGNOSTICS 
             10.9.1 ABILITY TO DETERMINE FOOD & DRUG ALLERGIES TO SUPPORT MARKET GROWTH
                        TABLE 308 IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 309 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 310 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 311 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 312 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 313 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
     10.1 DRUG MONITORING & TESTING 
             10.10.1 INCREASING ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
                        TABLE 314 KEY PRODUCTS FOR DRUG MONITORING
                        TABLE 315 KEY IVD PRODUCTS FOR DRUG TESTING
                        TABLE 316 IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 317 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 318 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 319 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 320 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 321 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
     10.11 BONE & MINERAL DISORDERS 
             10.11.1 RISING CASES OF OSTEOPOROSIS TO FUEL MARKET
                        TABLE 322 KEY PRODUCTS FOR BONE & MINERAL DISORDERS
                        TABLE 323 IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 324 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 325 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 326 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 327 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 328 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION)
     10.12 COAGULATION TESTING 
             10.12.1 INCREASING PREVALENCE OF HEMOPHILIA TO BOOST DEMAND
                        TABLE 329 IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 330 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 331 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 332 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 333 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 334 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR COAGULATION TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
     10.13 BLOOD GROUP TYPING 
             10.13.1 RISING NUMBER OF SURGICAL PROCEDURES TO SUPPORT MARKET DEMAND
                        TABLE 335 IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 336 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 337 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 338 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 339 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 340 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD GROUP TYPING, BY COUNTRY, 2021–2029 (USD MILLION)
     10.14 OTHER APPLICATIONS 
             TABLE 341 IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2029 (USD MILLION)
             TABLE 342 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 343 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 344 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 345 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 346 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION)
 
11 IN VITRO DIAGNOSTICS MARKET, BY END USER (Page No. - 327)
     11.1 INTRODUCTION 
             TABLE 347 IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
     11.2 HOSPITALS & CLINICS 
             11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO BOOST DEMAND
                        TABLE 348 IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 349 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 350 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 351 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 352 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 353 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)
     11.3 CLINICAL LABORATORIES 
             TABLE 354 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             TABLE 355 IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2029 (USD MILLION)
             TABLE 356 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 357 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 358 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 359 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 360 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
             11.3.1 LARGE REFERENCE LABORATORIES
                        11.3.1.1 Capability to conduct specific advanced tests to propel market
                                      TABLE 361 IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2021–2029 (USD MILLION)
                                      TABLE 362 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
                                      TABLE 363 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
                                      TABLE 364 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
                                      TABLE 365 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
                                      TABLE 366 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
             11.3.2 SMALL AND MEDIUM-SIZED LABORATORIES
                        11.3.2.1 Growing focus on POC device adoption to support market growth
                                      TABLE 367 IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY REGION, 2021–2029 (USD MILLION)
                                      TABLE 368 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
                                      TABLE 369 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
                                      TABLE 370 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
                                      TABLE 371 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
                                      TABLE 372 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR SMALL AND MEDIUM-SIZED LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
     11.4 BLOOD BANKS 
             11.4.1 RISING UTILIZATION OF ELISA TESTS TO PROPEL MARKET
                        TABLE 373 IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 374 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 375 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 376 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 377 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 378 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2029 (USD MILLION)
     11.5 HOME CARE SETTINGS 
             11.5.1 ADOPTION OF CONVENIENT AT-HOME ANTIGEN TESTS TO BOOST DEMAND
                        TABLE 379 IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 380 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 381 EUROPE: IVD MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 382 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 383 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 384 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)
     11.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             11.6.1 INCREASING FOCUS ON DRUG DISCOVERY DEVELOPMENT TO DRIVE MARKET
                        TABLE 385 IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 386 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 387 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 388 ASIA PACIFIC: IVD MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 389 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 390 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION)
     11.7 ACADEMIC INSTITUTES 
             11.7.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH
                        TABLE 391 IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2029 (USD MILLION)
                        TABLE 392 NORTH AMERICA: IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 393 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 394 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 395 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 396 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2029 (USD MILLION)
     11.8 OTHER END USERS 
             TABLE 397 IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2029 (USD MILLION)
             TABLE 398 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 399 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 400 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 401 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 402 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)
 
12 IN VITRO DIAGNOSTICS MARKET, BY REGION (Page No. - 358)
     12.1 INTRODUCTION 
             TABLE 403 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2021–2029 (USD MILLION)
     12.2 NORTH AMERICA 
             12.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 34 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
                        TABLE 404 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 405 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                        TABLE 406 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                        TABLE 407 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 408 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 409 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 410 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                        TABLE 411 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                        TABLE 412 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                        TABLE 413 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                        TABLE 414 NORTH AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.2.2 US
                        12.2.2.1 Established reimbursement framework and favorable policies for IVD providers to drive market
                                      TABLE 415 US: MACROECONOMIC INDICATORS
                                      TABLE 416 US: NUMBER OF IN VITRO TESTS CONDUCTED (BILLION)
                                      TABLE 417 US: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 418 US: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 419 US: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 420 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 421 US: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 422 US: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 423 US: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 424 US: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 425 US: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 426 US: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.2.3 CANADA
                        12.2.3.1 Favorable funding initiatives for early disease diagnosis to drive market
                                      TABLE 427 CANADA: ESTIMATED PREVALENCE OF DIABETES
                                      TABLE 428 CANADA: MACROECONOMIC INDICATORS
                                      TABLE 429 CANADA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 430 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 431 CANADA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 432 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 433 CANADA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 434 CANADA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 435 CANADA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 436 CANADA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 437 CANADA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 438 CANADA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
     12.3 EUROPE 
             12.3.1 EUROPE: RECESSION IMPACT
                        TABLE 439 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 440 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                        TABLE 441 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                        TABLE 442 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 443 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 444 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 445 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                        TABLE 446 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                        TABLE 447 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                        TABLE 448 EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                        TABLE 449 EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.3.2 GERMANY
                        12.3.2.1 Increasing investments in clinical diagnostics research to drive market
                                      TABLE 450 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 451 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 452 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 453 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 454 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 455 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 456 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 457 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 458 GERMANY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 459 GERMANY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.3.3 FRANCE
                        12.3.3.1 High healthcare expenditure and rising investments in genomic medicine to drive market
                                      TABLE 460 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 461 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 462 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 463 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 464 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 465 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 466 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 467 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 468 FRANCE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 469 FRANCE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.3.4 UK
                        12.3.4.1 Rising adoption of genome-based testing to drive market
                                      TABLE 470 UK: MACROECONOMIC INDICATORS
                                      TABLE 471 UK: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 472 UK: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 473 UK: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 474 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 475 UK: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 476 UK: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 477 UK: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 478 UK: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 479 UK: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 480 UK: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.3.5 ITALY
                        12.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth
                                      TABLE 481 ITALY: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 482 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 483 ITALY: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 484 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 485 ITALY: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 486 ITALY: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 487 ITALY: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 488 ITALY: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 489 ITALY: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 490 ITALY: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.3.6 SPAIN
                        12.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market
                                      TABLE 491 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 492 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 493 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 494 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 495 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 496 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 497 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 498 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 499 SPAIN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 500 SPAIN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.3.7 RUSSIA
                        12.3.7.1 High incidence of respiratory infectious diseases to boost demand
                                      TABLE 501 RUSSIA: MACROECONOMIC INDICATORS
                                      TABLE 502 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 503 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 504 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 505 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 506 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 507 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 508 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 509 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 510 RUSSIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 511 RUSSIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.3.8 SWITZERLAND
                        12.3.8.1 Rising prevalence of chronic diseases to support market growth
                                      TABLE 512 SWITZERLAND: MACROECONOMIC INDICATORS
                                      TABLE 513 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 514 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 515 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 516 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 517 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 518 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 519 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 520 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 521 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 522 SWITZERLAND: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.3.9 REST OF EUROPE
                        TABLE 523 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                        TABLE 524 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                        TABLE 525 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 526 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 527 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 528 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                        TABLE 529 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                        TABLE 530 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                        TABLE 531 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                        TABLE 532 REST OF EUROPE: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
     12.4 ASIA PACIFIC 
             FIGURE 35 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET SNAPSHOT
             TABLE 533 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
             TABLE 534 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
             TABLE 535 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
             TABLE 536 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
             TABLE 537 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
             TABLE 538 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
             TABLE 539 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
             TABLE 540 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
             TABLE 541 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
             TABLE 542 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
             TABLE 543 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.4.1 ASIA PACIFIC: RECESSION IMPACT
             12.4.2 JAPAN
                        12.4.2.1 Increasing research investments for immunoassays to drive market
                                      TABLE 544 JAPAN: MACROECONOMIC INDICATORS
                                      TABLE 545 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 546 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 547 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 548 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 549 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 550 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 551 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 552 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 553 JAPAN: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 554 JAPAN: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.4.3 CHINA
                        12.4.3.1 Growing focus on preventive care to boost demand
                                      TABLE 555 CHINA: MACROECONOMIC INDICATORS
                                      TABLE 556 CHINA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 557 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 558 CHINA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 559 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 560 CHINA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 561 CHINA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 562 CHINA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 563 CHINA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 564 CHINA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 565 CHINA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.4.4 INDIA
                        12.4.4.1 Rising incidence of diabetes and cancer to drive market
                                      TABLE 566 INDIA: MACROECONOMIC INDICATORS
                                      TABLE 567 INDIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 568 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 569 INDIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 570 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 571 INDIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 572 INDIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 573 INDIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 574 INDIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 575 INDIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 576 INDIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.4.5 SOUTH KOREA
                        12.4.5.1 Rising healthcare spending for innovative IVD technologies to support market growth
                                      TABLE 577 SOUTH KOREA: MACROECONOMIC INDICATORS
                                      TABLE 578 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 579 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 580 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 581 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 582 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 583 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 584 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 585 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 586 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 587 SOUTH KOREA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.4.6 AUSTRALIA
                        12.4.6.1 Increasing incidence of chronic diseases and rising blood donations to fuel market
                                      TABLE 588 AUSTRALIA: MACROECONOMIC INDICATORS
                                      TABLE 589 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 590 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 591 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 592 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 593 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 594 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 595 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 596 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 597 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 598 AUSTRALIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.4.7 REST OF ASIA PACIFIC
                        TABLE 599 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                        TABLE 600 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                        TABLE 601 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 602 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 603 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 604 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                        TABLE 605 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                        TABLE 606 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                        TABLE 607 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                        TABLE 608 REST OF ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
     12.5 LATIN AMERICA 
             12.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 609 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 610 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                        TABLE 611 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                        TABLE 612 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 613 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 614 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 615 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                        TABLE 616 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                        TABLE 617 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                        TABLE 618 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                        TABLE 619 LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.5.2 BRAZIL
                        12.5.2.1 Rising prevalence of diabetes to boost demand for IVD products
                                      TABLE 620 BRAZIL: MACROECONOMIC INDICATORS
                                      TABLE 621 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 622 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 623 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 624 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 625 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 626 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 627 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 628 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 629 BRAZIL: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 630 BRAZIL: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.5.3 MEXICO
                        12.5.3.1 Establishment of clinical laboratories to fuel uptake
                                      TABLE 631 MEXICO: MACROECONOMIC INDICATORS
                                      TABLE 632 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 633 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 634 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 635 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 636 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 637 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 638 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 639 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 640 MEXICO: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 641 MEXICO: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.5.4 REST OF LATIN AMERICA
                        TABLE 642 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                        TABLE 643 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                        TABLE 644 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 645 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 646 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 647 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                        TABLE 648 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                        TABLE 649 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                        TABLE 650 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                        TABLE 651 REST OF LATIN AMERICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
     12.6 MIDDLE EAST & AFRICA 
             12.6.1 GROWING FOCUS ON PRENATAL & CANCER TESTING TO DRIVE MARKET
                        TABLE 652 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                        TABLE 653 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                        TABLE 654 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 655 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 656 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 657 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                        TABLE 658 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                        TABLE 659 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                        TABLE 660 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                        TABLE 661 MIDDLE EAST & AFRICA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
     12.7 GCC COUNTRIES 
             12.7.1 GCC COUNTRIES: RECESSION IMPACT
                        TABLE 662 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
                        TABLE 663 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                        TABLE 664 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                        TABLE 665 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 666 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 667 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 668 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                        TABLE 669 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                        TABLE 670 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                        TABLE 671 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                        TABLE 672 GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.7.2 KINGDOM OF SAUDI ARABIA (KSA)
                        12.7.2.1 Rising government healthcare expenditure to boost demand
                                      TABLE 673 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 674 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 675 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 676 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 677 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 678 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 679 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 680 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 681 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 682 KINGDOM OF SAUDI ARABIA: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.7.3 UNITED ARAB EMIRATES (UAE)
                        12.7.3.1 Improvements in healthcare infrastructure to support market growth
                                      TABLE 683 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                                      TABLE 684 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                                      TABLE 685 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 686 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 687 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                                      TABLE 688 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                                      TABLE 689 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                                      TABLE 690 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                                      TABLE 691 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                                      TABLE 692 UNITED ARAB EMIRATES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
             12.7.4 OTHER GCC COUNTRIES
                        TABLE 693 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2029 (USD MILLION)
                        TABLE 694 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
                        TABLE 695 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 696 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 697 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2021–2029 (USD MILLION)
                        TABLE 698 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY SPECIMEN, 2021–2029 (USD MILLION)
                        TABLE 699 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION)
                        TABLE 700 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
                        TABLE 701 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION)
                        TABLE 702 OTHER GCC COUNTRIES: IN VITRO DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2021–2029 (USD MILLION)
 
13 COMPETITIVE LANDSCAPE (Page No. - 533)
     13.1 OVERVIEW 
     13.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 703 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN IVD MARKET
     13.3 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS 
             FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN IVD MARKET
     13.4 MARKET SHARE ANALYSIS 
             TABLE 704 IN VITRO DIAGNOSTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY
             FIGURE 37 IN VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2023)
     13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 
             13.5.1 STARS
             13.5.2 EMERGING LEADERS
             13.5.3 PERVASIVE PLAYERS
             13.5.4 PARTICIPANTS
                        FIGURE 38 COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2023
             13.5.5 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS
                        TABLE 705 COMPANY FOOTPRINT ANALYSIS
                        TABLE 706 COMPANY PRODUCT & SERVICE FOOTPRINT
                        TABLE 707 COMPANY TECHNOLOGY FOOTPRINT
                        TABLE 708 COMPANY APPLICATION FOOTPRINT
     13.6 START UP/SME EVALUATION MATRIX, 2023 
             13.6.1 PROGRESSIVE COMPANIES
             13.6.2 RESPONSIVE COMPANIES
             13.6.3 DYNAMIC COMPANIES
             13.6.4 STARTING BLOCKS
                        FIGURE 39 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2023
             13.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES
                        TABLE 709 IN VITRO DIAGNOSTICS MARKET: KEY START-UPS/SMES
     13.7 COMPETITIVE SCENARIO 
             13.7.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS
                        TABLE 710 IN VITRO DIAGNOSTICS MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS (JANUARY 2020–JANUARY 2024)
             13.7.2 DEALS
                        TABLE 711 IN VITRO DIAGNOSTICS MARKET: DEALS (JANUARY 2020–JANUARY 2024)
             13.7.3 EXPANSIONS
                        TABLE 712 IN VITRO DIAGNOSTICS MARKET: EXPANSIONS (JANUARY 2020−JANUARY 2024)
             13.7.4 OTHER DEVELOPMENTS
                        TABLE 713 IN VITRO DIAGNOSTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020−JANUARY 2024)
     13.8 BRAND/PRODUCT COMPARISON 
                        TABLE 714 BRAND/PRODUCT COMPARISON FOR IN VITRO DIAGNOSTICS INSTRUMENTS
 
14 COMPANY PROFILES (Page No. - 551)
     14.1 KEY PLAYERS 
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
             14.1.1 DANAHER CORPORATION
                        TABLE 715 DANAHER: COMPANY OVERVIEW
                        FIGURE 40 DANAHER: COMPANY SNAPSHOT (2023)
             14.1.2 ROCHE DIAGNOSTICS
                        TABLE 716 ROCHE DIAGNOSTICS: COMPANY OVERVIEW
                        FIGURE 41 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2023)
             14.1.3 ABBOTT
                        TABLE 717 ABBOTT: COMPANY OVERVIEW
                        FIGURE 42 ABBOTT: COMPANY SNAPSHOT (2023)
             14.1.4 SIEMENS HEALTHINEERS AG
                        TABLE 718 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
                        FIGURE 43 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
             14.1.5 THERMO FISHER SCIENTIFIC INC.
                        TABLE 719 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
             14.1.6 ILLUMINA, INC.
                        TABLE 720 ILLUMINA, INC.: COMPANY OVERVIEW
                        FIGURE 45 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
     4.1.7 HOLOGIC, INC. 
                        TABLE 721 HOLOGIC, INC.: COMPANY OVERVIEW
                        FIGURE 46 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
             14.1.8 BIO-RAD LABORATORIES, INC.
                        TABLE 722 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
                        FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
             14.1.9 BIOMÉRIEUX
                        TABLE 723 BIOMÉRIEUX: COMPANY OVERVIEW
                        FIGURE 48 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
             14.1.10 SYSMEX CORPORATION
                        TABLE 724 SYSMEX CORPORATION: COMPANY OVERVIEW
                        FIGURE 49 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
             14.1.11 REVVITY
                        TABLE 725 REVVITY: COMPANY OVERVIEW
                        FIGURE 50 REVVITY: COMPANY SNAPSHOT (2023)
             14.1.12 BECTON, DICKINSON AND COMPANY
                        TABLE 726 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
                        FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
             14.1.13 AGILENT TECHNOLOGIES, INC.
                        TABLE 727 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
                        FIGURE 52 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
             14.1.14 QIAGEN N.V.
                        TABLE 728 QIAGEN N.V.: COMPANY OVERVIEW
                        FIGURE 53 QIAGEN N.V.: COMPANY SNAPSHOT (2023)
             14.1.15 DIASORIN S.P.A.
                        TABLE 729 DIASORIN S.P.A: COMPANY OVERVIEW
                        FIGURE 54 DIASORIN S.P.A: COMPANY SNAPSHOT (2023)
             14.1.16 GRIFOLS S.A
                        TABLE 730 GRIFOLS S.A: COMPANY OVERVIEW
                        FIGURE 55 GRIFOLS S.A: COMPANY SNAPSHOT (2023)
             14.1.17 WERFEN S.A.
                        TABLE 731 WERFEN S.A: COMPANY OVERVIEW
                        FIGURE 56 WERFEN S.A: COMPANY SNAPSHOT (2023)
             14.1.18 QUIDELORTHO CORPORATION
                        TABLE 732 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
                        FIGURE 57 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)
     14.2 OTHER PLAYERS 
             14.2.1 DEVYSER
                        TABLE 733 DEVYSER: COMPANY OVERVIEW
                        FIGURE 58 DEVYSER: COMPANY SNAPSHOT (2023)
             14.2.2 CHEMBIO DIAGNOSTICS, INC.
                        TABLE 734 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW
                        FIGURE 59 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
             14.2.3 SURMODICS, INC.
                        TABLE 735 SURMODICS, INC.: COMPANY OVERVIEW
                        FIGURE 60 SURMODICS, INC.: COMPANY SNAPSHOT (2023)
             14.2.4 MENARINI SILICON BIOSYSTEMS
                        TABLE 736 MENARINI SILICON BIOSYSTEMS: COMPANY OVERVIEW
             14.2.5 SPEEDX PTY. LTD.
                        TABLE 737 SPEEDX PTY. LTD.: COMPANY OVERVIEW
             14.2.6 GENSPEED BIOTECH GMBH
                        TABLE 738 GENSPEED BIOTECH GMBH: COMPANY OVERVIEW
             14.2.7 MERCK KGAA
                        TABLE 739 MERCK KGAA: COMPANY OVERVIEW
             14.2.8 CARIS LIFE SCIENCES, INC.
                        TABLE 740 CARIS LIFE SCIENCES, INC.: COMPANY OVERVIEW
             14.2.9 ARKRAY, INC.
                        TABLE 741 ARKRAY, INC.: COMPANY OVERVIEW
             14.2.10 ACCELERATE DIAGNOSTICS, INC.
                        TABLE 742 ACCELERATE DIAGNOSTICS, INC.: COMPANY OVERVIEW
             14.2.11 CELLABS
                        TABLE 743 CELLABS: COMPANY OVERVIEW
             14.2.12 J. MITRA & CO. PVT. LTD.
                        TABLE 744 MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
             14.2.13 EPITOPE DIAGNOSTICS, INC.
                        TABLE 745 EPITOME DIAGNOSTICS, INC.: COMPANY OVERVIEW
             14.2.14 BOSTER BIOLOGICAL TECHNOLOGY
                        TABLE 746 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
             14.2.15 ENZO BIOCHEM, INC.
                        TABLE 747 ENZO BIOCHEM, INC: COMPANY OVERVIEW
             14.2.16 GENETIC SIGNATURES
                        TABLE 748 GENETIC SIGNATURES: COMPANY OVERVIEW
             14.2.17 SAVYON DIAGNOSTICS LTD.
                        TABLE 749 SAVYON DIAGNOSTICS LTD.: COMPANY OVERVIEW
             14.2.18 TRIVITRON HEALTHCARE
                        TABLE 750 TRIVITRON HEALTHCARE: COMPANY OVERVIEW
             14.2.19 MDXHEALTH SA
                        TABLE 751 MDXHEALTH SA: COMPANY OVERVIEW
             14.2.20 CREATIVE DIAGNOSTICS
                        TABLE 752 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
             14.2.21 INBIOS INTERNATIONAL, INC.
                        TABLE 753 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
             14.2.22 MACCURA BIOTECHNOLOGY CO., LTD.
                        TABLE 754 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
             14.2.23 VELA DIAGNOSTICS
                        TABLE 755 VELA DIAGNOSTICS: COMPANY OVERVIEW
 
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
 
15 APPENDIX (Page No. - 696)
     15.1 DISCUSSION GUIDE 
     15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     15.3 CUSTOMIZATION OPTIONS 
     15.4 RELATED REPORTS 
     15.5 AUTHOR DETAILS 

The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as product launches and approvals, expansions, and collaborations of the leading players, the competitive landscape of the in vitro diagnostics market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the in vitro market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was conducted after acquiring knowledge about the in vitro diagnostics market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as hospital directors, clinic personnel, and Research scientists) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC countries. Approximately 45% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted fosr the remaining 55%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

In Vitro Diagnostics Market Size, and Share

Note 1: Others include sales, marketing, and product managers.

Note 2: Tiers of companies are defined based on their total revenue. As of 2023, Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Abbott Laboratories

Head of Marketing

Danaher Corporation

Director of Research and Development

Thermo Fisher Scientific

Sales Manager

Siemens Healthineers

VP Marketing

Market Size Estimation

All major product manufacturers offering various in vitro diagnostics were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value of in vitro diagnostics market was also split into various segments and subsegments at the region and country level based on:

  • Product and services mapping of various manufacturers for each type of in vitro diagnostics market at the regional and country-level
  • Relative adoption pattern of each IVD market among key application segments at the regional and/or country-level
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country level

Global In Vitro Diagnostics Market Size: BottonmUp Approach

In Vitro Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global In Vitro Diagnostics Market Size: Top Down Approach

In Vitro Diagnostics Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the in vitro diagnostics industry.

Market Definition

IVD tests are non-invasive tests performed to diagnose, monitor, screen, and assess diseases and health conditions. IVD has a broad scope ranging from sophisticated technologies performed in clinical laboratories to simple and easy-to-use rapid testing kits.

Key Stakeholders

  • IVD Instrument Manufacturers
  • Hospitals and Clinics
  • Research Institutes
  • Distributors of IVD Products

Report Objectives

  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To define, describe, segment, and forecast the in vitro diagnostics market by product & service, by specimen, by technology, by test type, application, end user, and region
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall IVD market
  • To forecast the size of the in vitro diagnostics market in six main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, Middle East & Africa, and GCC Countries.
  • To profile key players in the IVD market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments, such as product launches and approvals; expansions; and collaborations, of the leading players in the in vitro diagnostics market
  • To benchmark players within the IVD market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

MarketsandMarkets offers the following customizations for this market report

Country Information

  • Additional country-level analysis of the in vitro diagnostics market

Company profiles

  • Additional three company profiles of players operating in the in vitro diagnostics market.

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the in vitro diagnostics market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 3609
Published ON
Mar, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the In Vitro Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback